论文部分内容阅读
原发性肝癌(PLC,以下简称肝癌)是临床上常见的恶性肿瘤之一,全球发病率逐年增长,已超过62.6万/年,居于恶性肿瘤的第5位;死亡接近60万/年,位居肿瘤相关死亡的第3位。肝癌在我国高发,目前,我国发病人数约占全球的55%;在肿瘤相关死亡中仅次于肺癌,位居第二。手术切除一直被认为是治疗肝癌的首选方法,但只有10%～30%的患者具有外科手术的指征,手术后5年生存率为31%～56%。目前,肝癌非手术
Primary liver cancer (PLC, hereinafter referred to as liver cancer) is one of the most common malignant tumors in clinic. The global incidence has been increasing year by year, exceeding 626,000 / year, ranking the fifth in malignant tumors; the death rate is nearly 600,000 / year. Ranking third in cancer-related deaths. High incidence of liver cancer in our country, at present, China’s incidence of about 55% of the world’s total; second only to lung cancer after cancer-related deaths, ranking second. Surgical resection has long been considered as the first choice for the treatment of liver cancer. However, only 10% to 30% of patients have surgical indications. The 5-year survival rate after surgery is 31% -56%. At present, liver cancer is non-surgical